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Abstract
Objective To inform decision making regarding intervention strategies
against non-communicable diseases in Mexico, in the context of health
reform.
Design Cost effectiveness analysis based on epidemiological modelling.
Interventions 101 intervention strategies relating to nine major clusters
of non-communicable disease: depression, heavy alcohol use, tobacco
use, cataracts, breast cancer, cervical cancer, chronic obstructive
pulmonary disease, cardiovascular disease, and diabetes.
Data sources Mexican data sources were used for most key input
parameters, including administrative registries; disease burden and
population estimates; household surveys; and drug price databases.
These sources were supplemented as needed with estimates for Mexico
from the WHO-CHOICE unit cost database or with estimates extrapolated
from the published literature.
Main outcome measures Population health outcomes, measured in
disability adjusted life years (DALYs); costs in 2005 international dollars
($Int); and costs per DALY.
Results Across 101 intervention strategies examined in this study,
average yearly costs at the population level would range from around
≤$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies
for primary prevention in cardiovascular disease. Wide variation also
appeared in total population health benefits, from <1000 DALYs averted
a year (for some components of cancer treatments or aspirin for acute
ischaemic stroke) to >300 000 averted DALYs (for aggressive
combinations of interventions to deal with alcohol use or cardiovascular
risks). Interventions in this study spanned a wide range of average cost
effectiveness ratios, differing by more than three orders of magnitude
between the lowest and highest ratios. Overall, community and public
health interventions such as non-personal interventions for alcohol use,
tobacco use, and cardiovascular risks tended to have lower cost
effectiveness ratios than many clinical interventions (of varying
complexity). Even within the community and public health interventions,
however, there was a 200-fold difference between the most and least
cost effective strategies examined. Likewise, several clinical interventions
appeared among the strategies with the lowest average cost
effectiveness ratios—for example, cataract surgeries.
Conclusions Wide variations in costs and effects exist within and across
intervention categories. For every major disease area examined, at least
some strategies provided excellent value for money, including both
population based and personal interventions.
Correspondence to: J A Salomon jsalomon@hsph.harvard.edu
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Research
RESEARCHIntroduction
In 2003, Mexico introduced a major health reform that created
the System of Social Protection in Health (SSPH).
1 SSPH
generated new financial rules to fund population based
interventions for all Mexicans regardless of their insurance
status and personal healthcare interventions for those without
accesstosocialsecurity(abouthalfofthetotalpopulation).The
latter were financed through an insurance based component
calledSeguroPopular.Throughthereforms,publicexpenditure
for the uninsured increased substantially,
2 with the overall
budget for the Ministry of Health rising by almost four times
in real terms between 2001 and 2010.
3 By the end of 2010, the
number of Seguro Popular beneficiaries had reached over 43
million, 88% of the previously uninsured target population.
4
Duringtheplanninganddesignofthereform,rigorousevidence
was needed on the magnitude of different health problems and
on the benefits and costs of different health interventions.
Decisions to include new interventions in explicitly defined
packages of services were informed by a deliberative process
that included an analytical priority setting exercise based on
measurement of the burden of disease and cost effectiveness of
differentcandidateinterventions.
5StatesinMexicoarerequired
toprovideallinterventionsincludedinthreeminimumpackages
of services comprising community and public health
interventions; low and medium complexity clinical services;
and high complexity clinical services, each financed through
separatefundingmechanisms.Aspartoftheprocessofdefining
thecontentofthesepackagesduring2004–6,weundertookcost
effectiveness analyses for a wide array of health interventions
spanningmajorcausesofdiseaseburdeninMexico.Theoverall
process of defining the content of the service packages was
intended to be evidence based, equitable, transparent, and
contestable. After the reform, evidence on cost effectiveness
continues to inform decision making regarding amendments to
the packages of services covered by SSPH; state level policies
regarding coverage of interventions additional to the defined
minimum packages; and broader debates over the advantages
and disadvantages of explicit packaging based in part on
economic evidence—for example, among social security
institutions in Mexico that do not currently base coverage
decisions on explicit packages of interventions.
This paper—as part of a series on the cost effectiveness of
interventions for non-communicable disease and injury in
economicallydevelopingregionsoftheworld—reportsoncost
effectiveness analyses for 101 intervention strategies directed
atninemajorclustersofnon-communicablediseasesinMexico.
Methods
Our analyses focused on interventions related to the following
nine disease areas that are major contributors to the overall
burden of disease in Mexico
5 6: depression, heavy alcohol use,
tobacco use, cataracts, breast cancer, cervical cancer, chronic
obstructive pulmonary disease, cardiovascular disease, and
diabetes.Interventionsforanalysiswereselectedinconsultation
withtheMinistryofHealthinMexico,basedonpolicypriorities
and ongoing debates regarding the content of packages of
services in SSPH. Intervention definitions were developed
according to standards of quality care and available evidence
on effectiveness. The table⇓ summarises the main types of
interventionsanalysedinthisstudy,notingthespecificpackage
of services for which each type of intervention was considered.
The technical appendix on bmj.com provides a full listing and
definitions of the 101 specific interventions that we evaluated.
The overall analytical approach used in this study adhered to
recommendationsforundertakinggeneralisedcosteffectiveness
analysis in the WHO-CHOICE framework.
7 Where prior
regional analyses were available from the WHO-CHOICE
project,
8-13 we used similar intervention definitions, modelling
approaches, and costing methods. Here we summarise the
methods and assumptions used in the analyses. Further details
are provided in the technical appendix on bmj.com.
Analytic overview
To compute the effectiveness of an intervention targeting a
particular health problem in terms of net changes in population
health, we first defined the current epidemiology of the health
problem, building on a linked study to measure the burden of
disease in Mexico.
6 Intervention effectiveness was expressed
in terms of changes in disease model parameters—that is, as
changes in rates of incidence, prevalence, case fatality, or
remission or changes in health state valuations that reflect the
severity of a particular health outcome. We used a population
modeltotranslateinformationondiseasedynamicsintogeneric,
comparable measures of population health, expressed as
disabilityadjustedlifeyears(DALYs).InlinewithWHOglobal
burden of disease estimation,
14 the Mexican national burden of
disease assessment related to this project,
6 and standard
WHO-CHOICEmethods,
7DALYsavertedwerediscounted(at
3% a year) and age weighted (see also the general appendix on
bmj.com). Costs were evaluated from a societal perspective,
within three broad categories: patient costs, programme costs,
andtrainingcosts.Costswereexpressedasinternationaldollars
($Int) at 2005 prices, discounted at 3% a year according to
CHOICE standards.
7 International dollars represent a
hypothetical currency that allows for the same quantities of
goods or services to be purchased regardless of country,
standardised on purchasing power in the United States.
Data sources
We used Mexican data sources when possible, drawing
extensivelyonfourmainlocalsources:administrativeregistries,
population estimates, household surveys, and drug cost
databases.
Administrative registry data
Information on age specific mortality and causes of death are
compiled from death certificates by the Ministry of Health and
the Instituto Nacional de Estadística y Geografía. Additionally,
publicinstitutionsprovidinghospitalservicesmaintaindischarge
registries, which include patient level information on
sociodemographic characteristics, causes of admission to
hospitalclassifiedbyICD-10codes(internationalclassification
ofdiseases,10threvision),diagnosticandtreatmentprocedures
coded according to ICD-9-CM, result of procedures, mortality
in hospital, reasons for discharge, number of hospital bed days,
andinsurancestatus.Forthepresentanalyses,weusedmortality
data from the year 2004. We used discharge registries from
Ministry of Health hospitals for the years 2000–5 and from
hospitalsaffiliatedwiththeInstitutoMexicanodelSeguroSocial
(IMSS) for the years 2004 and 2005.
Population estimates
Population estimates for 2000–5 were provided by the Consejo
Nacional de Población (CONAPO), which develops yearly
projections of population numbers by age, sex, state, and
insurancestatus.Projectionsaremadebasedonofficialsurveys
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and special surveys relating to migration.
Population household surveys
TheEncuestaNacionaldeSaludyNutrición2005–6(ENSANut)
was a nationally and state representative survey that sampled
47 695 households and 206 700 individuals. Modules in
ENSANut included information on household characteristics,
health insurance, risk factors (smoking and alcohol use), health
states, and use of services. Biomarkers were collected on
concentrationsofcholesterol,plasmaglucose,andhaemoglobin
A1c and blood pressure. ENSANut 2005–6 was used in this
analysis primarily to measure current coverage of selected
interventions.
Drug cost database
Public institutions providing healthcare in Mexico are required
to purchase only drugs included in the Cuadro Básico de
Medicamentos(MexicanPositiveList,MPL).Publicpurchasing
regulations require public bidding for multiple source drugs,
although there is no general consolidated purchase system for
the whole public health sector, as all institutions are essentially
independent.Weusedthe2005purchasepricedatabaseavailable
from IMSS, which is the largest public purchaser in Mexico.
Estimation of intervention effects
Epidemiological estimates
For most interventions, current epidemiology of relevant
diseases or injuries was defined based on results from the
Mexican burden of disease analysis,
6 expressed in terms of age
and sex specific incidence, prevalence, case fatality, remission,
and mortality. Vital registration data for 2004 were used to
estimatemortalitybyage,sex,andcause.Totalmortalityfigures
by age and sex were adjusted with standard demographic
techniques to account for under-recording of deaths at certain
ages, misreporting of age on the death certificate, and
migration.
15 16 Estimates for causes of death were adjusted
following standard algorithms for redistributing deaths coded
to“illdefined”diseaseorinjurycategories,cancersofunknown
sites, and cardiovascular disease, as well as miscoding of
diabetes to cardiovascular or other chronic diseases.
6 17-19
Estimatesoftheincidenceofdifferentdiseasesandtheirrelevant
sequelae by age and sex were derived from a combination of
sources and imputation approaches applied to different groups
of causes.
6
Intervention definitions
The selection and specification of interventions, in cases where
aWHO-CHOICEregionalanalysiswasavailable,corresponded
closelytotheinterventionsdefinedintheprioranalysis.Incases
where no WHO-CHOICE regional analysis was available, the
choiceofinterventionswasguidedbyconsultationwithexperts
in Mexico or by existing norms for clinical practice in Mexico.
Definitionofinterventions,ingeneral,wasasexplicitaspossible
and specified both immediate components of intervention
deliveryaswellasthetypesofactionsthatwouldbeundertaken
inresponsetodownstreamconsequencesofthediseaseprocess
or of the intervention itself.
Intervention effectiveness
The definition of the current epidemiology, combined with
information on current coverage and effectiveness of
interventions, served as the analytic starting point for defining
allinterventionscenarios,includingthenullscenario.Following
thestandardWHO-CHOICEapproach,wederivedintervention
effectivenessfrommeta-analysesandsystematicreviewswhere
these were available. For interventions that were examined
previouslyinWHO-CHOICEregionalanalyses,wemaintained
consistent assumptions about intervention efficacy unless there
wassufficientevidencetosuggestdifferentoutcomesinMexico.
For incorporation into the population model described below,
interventioneffectivenesswastranslatedintochangesinrelevant
disease model parameters. For example, the effects of primary
prevention were expressed as percent reductions in age and sex
specific incidence rates from a particular condition, while
treatment interventions were allowed to affect transitions to
otherdiseasestates,remissionrates,casefatalityrates,orhealth
state valuations. Details on the parameters of effectiveness for
specific intervention analyses are provided in the technical
appendix on bmj.com, including a full listing of data sources
on effectiveness.
Population health outcomes
Population health outcomes under different intervention
scenarios were modelled with the multistate population model
PopMod
20(seegeneralappendixonbmj.com)oranalogoustools
developed for this project where more detailed disease models
wererequired.Interventionswerecomparedwithanullscenario,
which was simulated by altering the baseline epidemiological
parameters to remove the estimated effects of current
interventioncoverage.Forinterventionscenarios,effectiveness
estimates were adjusted to account for target population
coverage levels and provider and patient adherence to
interventions. Each intervention scenario assumed
implementation of the intervention for a 10 year period, but the
population model captured all effects over a 100 year time
horizon.Forboththenullandinterventionscenarios,theinputs
to the population model included rates of incidence, remission,
and case fatality; estimates of prevalence; and health state
valuations for relevant outcomes. Outputs from the model
included estimates of the residence time in each disease state
and total number of healthy life years lived by age, sex, and
calendaryear.Theseoutputswereusedtocalculateintervention
effectiveness in terms of changes in aggregate population level
health outcomes. Where alternatives to PopMod were used for
specific analyses, these alternative modelling approaches are
described in the technical appendix on bmj.com.
Estimation of intervention costs
We used an ingredients approach to costing, by which the
quantitiesofinputsthatareusedindeliveringaparticularservice
or intervention are multiplied by their unit prices to obtain total
costs. Following the standard WHO-CHOICE approach, we
considered three broad categories of costs: patient costs,
programme costs, and training costs.
Patient costs
Patient level costs included hospital bed days, hospital visits,
health centre visits, ancillary care, laboratory and diagnostic
tests, drugs, and other costs related to specific interventions.
Resource quantities were derived through review of the
published literature, and from practice guidelines. Drug prices
were taken from the IMSS purchase price database. Unit prices
fornon-tradedgoods,includingpatientservicessuchashospital
bed days, were standardised across intervention analyses and
derivedfromtheWHO-CHOICEpricedatabase,whichincludes
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multinational datasets on costs.
21
Programme costs
We considered several key categories of programme activities.
Basic administration includes planning and overhead costs, in
addition to staff required to effectively monitor, evaluate, and
supervise the programme. These costs depend on whether the
intervention requires legislation, the level at which
administration is required, and the complexity of monitoring
and evaluation needed. Other categories of programme costs
relevant to certain interventions included media campaigns,
other information, education or communication activities, and
lawenforcement.Formostinterventions,weadoptedestimates
ofresourceuseandpricesforprogrammecostcomponentsfrom
previous WHO-CHOICE regional analyses. Details on
assumptionsofprogrammecostsforspecificanalysesareinthe
technical appendix (see bmj.com).
Training costs
Training costs, relevant for some interventions, depend on the
length of training required, the number of supervisory visits
neededayear,andthecapacityforasingletrainingsession.All
interventions in this study that required training costs were
linked to previous WHO-CHOICE regional analyses, and we
maintained the assumptions from these previous analyses.
Estimation of cost effectiveness
We computed total costs for a given intervention as the sum of
all patient, programme, and training costs. The null scenario by
definition includes no costs, so costs of all other interventions
can be interpreted as being incremental on the null. The total
healthbenefitsofaninterventionwerecomputedbycomparing
the number of healthy life years lived in the population in a
particularinterventionscenariowiththetotalnumberofhealthy
life years lived in the population under the null scenario. In the
base case, we used discounted age weighted DALYs as the unit
of account for healthy life years, but we also conducted a
sensitivity analysis comparing these results with those without
age weighting.
For all interventions, we report annualised quantities for both
total costs and total benefits. For total costs, these were derived
simplybydividingthecostsoverthe10yearinterventionperiod
by 10. For total benefits, these were derived by taking the full
difference in health effects over the 100 year modelled period
and dividing this by 10. In this way, the annualised costs and
benefits can be interpreted as the costs and benefits associated
with a single year of intervention. We report average cost
effectiveness ratios for interventions, ordered by increasing
overalleffects.Averagecosteffectivenessratiosareinterpretable
as the net costs per unit of net benefit associated with delivering
the intervention, compared with doing nothing. We also report
incremental cost effectiveness ratios where these measures are
relevant—thatis,inevaluatingmutuallyexclusiveinterventions
thatrepresentcompetingchoices.Incrementalcosteffectiveness
ratios were computed for an intervention with respect to the
next most effective alternative after eliminating strategies that
were dominated (that is, those that were more costly and less
effective than other options) or those that were weakly
dominated (that is, had higher cost effectiveness ratios than
more effective options).
Following the standard benchmarks for value for money
proposed in international work on cost effectiveness, we
compared cost effectiveness ratios against thresholds defined
in reference to the gross domestic product (GDP) per capita in
Mexico, which was $Int10 770 in 2005. Interventions were
considered to be highly cost effective when they had ratios that
fell below the per capita GDP and were regarded as being
potentially cost effective if they had ratios between one and
three times per capita GDP.
Results
Overview
Thefigure⇓summarisesinformationoncosts,populationhealth
effects, and cost effectiveness (compared with the null) for all
interventions. Across the 101 interventions examined in this
study, the average yearly costs at the population level ranged
from ≤$Int1m (for cataract surgeries and some elements of
cervical cancer treatment) to >$Int1bn (for high coverage of
treatmentforhypercholesterolaemiaoraggressivemanagement
ofabsolutecardiovascularrisks).Comparingthetotalannualised
population health benefits across interventions, we again
observedawiderangeofoutcomes,from<1000DALYsaverted
a year (for some components of cancer treatments or aspirin for
acuteischaemicstroke)to>300000DALYsavertedayear(for
aggressive combination of interventions to deal with alcohol
use, which was the leading risk factor for the burden of disease
in Mexico in 2004,
6 and cardiovascular risks).
Inthefigure⇓,withbothaxesdisplayedonalogscale,diagonal
lines moving from the lower left to the upper right direction are
cost effectiveness isoquants, which means that any point on the
same line as another point has the same average cost
effectiveness ratio compared with the null. Thus, these figures
offer an easy graphical display of broad bands of cost
effectiveness across interventions. The interventions in this
studyspannedawiderangeofaveragecosteffectivenessratios,
differing by more than three orders of magnitude between the
lowest and highest ratios. At the low end, some interventions
cost<$Int100perDALYaverted,suchastaxationinterventions
for alcohol. At the high end, we identified interventions that
cost >$Int100 000 per DALY, such as high intensity treatment
for chronic obstructive pulmonary disease or aspirin for acute
ischaemic stroke.
Comparison across intervention packages
The interventions in this analysis pertained to three different
packagesofinterventionscoveredbythehealthreformscheme:
community and public health interventions; low and medium
complexity clinical interventions; and high complexity clinical
interventions.Thereformspecifiedthateachofthesecategories
of interventions should be financed from a separate fund. The
figure⇓distinguishesinterventionsfallingintothesethreebroad
categories. The community and public health interventions
included non-personal interventions for alcohol use, tobacco
use, and cardiovascular risks; and screening for breast cancer
and cervical cancer. Overall, the community and public health
interventions tended to have high benefits and medium level
overall costs and tended to have lower cost effectiveness ratios
thanmanyoftheinterventionsintheothertwocategories.Even
withinthecommunityandpublichealthinterventions,however,
there was more than a 200-fold difference between the highest
and lowest cost effectiveness ratios.
Lowandmediumcomplexityhealthcareinterventionsincluded
personal services for alcohol use, tobacco use, and
cardiovascular disease prevention; treatment for chronic
obstructive pulmonary disease; interventions for depression;
cataract surgery; and secondary prevention for diabetes. High
complexity healthcare interventions included treatment for
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treatmentforbreastcancerandcervicalcancer.Intermsoftotal
costsandtotalbenefits,thehighcomplexityinterventionstended
to have lower totals than the low and medium complexity
interventions, mainly because the target populations for these
servicesweresmalleronaverage.Intermsofcosteffectiveness
ratios, on the other hand, there was little discernable difference
between the two groups of interventions. Cost effectiveness
ratios both for low and medium complexity interventions and
for high complexity interventions spanned ranges of more than
three orders of magnitude.
Results by disease cluster
Full results on the yearly costs, population effects, and cost
effectiveness ratios for all 101 interventions are provided in the
appendix table on bmj.com. Here we summarise the costs,
effects, and average cost effectiveness results by intervention
cluster. The average cost effectiveness ratio can be understood
asthecosteffectivenessofaninterventioncomparedwithanull
scenario(nointervention).Whenwecomparemutuallyexclusive
interventionswithinacluster,wealsodescribeincrementalcost
effectiveness ratios, which were based on the net costs and net
effectsofaninterventioncomparedwiththenextmosteffective,
non-dominated intervention.
Depression—We evaluated four main interventions for the
treatment of depression—older antidepressant drugs (tricyclic
antidepressants), newer antidepressants (selective serotonin
reuptake inhibitors), psychotherapy, and proactive case
management—as well as various combinations of these
interventions.Wefoundthatproactivecarecombinedwitholder
or newer antidepressants had the biggest impact on population
health, averting almost double the number of DALYs averted
by psychotherapy or antidepressants alone. All examined
strategies had average cost effectiveness ratios below the per
capita GDP in Mexico for each DALY averted, making them
cost effective by international standards. Regarding all
interventionsandcombinationsasmutuallyexclusivecompeting
choices, we found that two interventions dominated all others:
newerantidepressantscomparedwiththestatusquo,whichhad
an incremental cost effectiveness ratio <$Int1500 per DALY
averted, and the combination of newer antidepressants with
psychotherapy and proactive management, which had an
incrementalcosteffectivenessratioaround$Int3400perDALY
averted.
Heavy alcohol use—We evaluated five main types of
interventionsforheavyalcoholuse(includingtaxationatvarious
levels, random roadside breath testing, brief advice in primary
healthcare, reduced access at retail sales locations, and a
comprehensiveadvertisingban)aswellasvariouscombinations
of these interventions. We found that taxation interventions
producedthehighestoverallpopulationhealthbenefitsandwere
also among the lowest cost interventions in this group. The
taxation interventions, along with interventions to reduce retail
access and limit advertising, all had highly attractive cost
effectivenessratioscomparedwithdoingnothing(<$Int350per
DALY averted, or <$Int100 per DALY averted in the case of
the tax interventions). Even the interventions with the highest
cost effectiveness ratios in this cluster (breath testing and brief
physician advice) had costs per DALY below the per capita
GDP of Mexico, making them highly cost effective by
international standards. Considering the incremental costs and
effects of interventions treated as competing choices, we found
that an aggressive tax increase had an incremental cost
effectiveness ratio of only $Int72 per DALY averted compared
with the null (and dominated the status quo); adding a ban on
advertising yielded an incremental cost effectiveness ratio of
$Int320perDALYavertedcomparedwithonlythetaxincrease.
Combining the tax increase, advertising ban, brief advice, and
reduced access had an incremental cost effectiveness ratio
around $Int1800, and adding roadside breath testing produced
an incremental cost effectiveness ratio around I$10 900, which
is close to the GDP per capita in Mexico.
Tobacco use—We evaluated four main types of interventions
fortobaccouse(taxationatdifferentlevels,cleanindoorairlaw
enforcement,nicotinereplacementtherapy,andacomprehensive
advertisingban)andseveralcombinationsoftheseinterventions.
As with alcohol, we found that taxation interventions were
effective in terms of population health benefits, inexpensive
compared with other interventions, and highly cost effective.
Acomprehensiveadvertisingbanandcleanairlawenforcement
would also be characterised as highly cost effective using the
benchmark of averting each DALY at a cost of less than
Mexico’sGDPpercapita,whereasnicotinereplacementtherapy
exceededthethresholdofthreetimesGDPpercapitaperDALY
averted, which made this intervention not cost effective
accordingtointernationalstandards.Intheincrementalanalysis,
increased taxation had an incremental cost effectiveness ratio
of around $Int140 per DALY averted compared with the status
quo; adding a ban on advertising produced an incremental cost
effectiveness ratio of $Int2800.
Cataract—Theonlyeffectivetreatmentforcataractsiscataract
surgerytoremovetheopacifiedlens.Weevaluatedtwodifferent
types of cataract surgery: conventional extracapsular cataract
extraction and phacoemulsification. Both procedures were
assessed at three target coverage levels (50%, 80%, and 95%)
for a total of six separate intervention analyses. Both surgeries,
at any coverage level, were found to have average cost
effectiveness ratios below $Int100, making them among the
mostcosteffectiveofallinterventionsexaminedacrossdifferent
clusters. In terms of comparisons between the different types,
phacoemulsificationdominatedextracapsularcataractextraction
at any given coverage level. At a coverage of 95%,
phacoemulsificationhadanincrementalcosteffectivenessratio
of $Int43 per DALY averted compared with extracapsular
cataract extraction at 95% coverage.
Breast cancer—We evaluated treatment of breast cancer,
including a disaggregated analysis of costs and effects of
treatment at different stages, as well as a strategy of treatment
plus routine population screening according to the Mexican
norm at the time of analysis. Considering the benefits of
treatment, we found that treating tumours at earlier stages
contributedgreaterhealthbenefitsoverallthantreatmentatlater
stagesandthatpopulationscreening,whilecostly,wouldprovide
substantial additional benefits over clinical detection. The cost
effectiveness ratios for breast cancer treatment fell below
Mexico’spercapitaGDPperDALYaverted,makingtreatment
highly cost effective. Adding screening to treatment according
to the norm at the time of analysis had an incremental cost
effectiveness ratio of $Int22 000 (that is, falling between one
and three times GDP per capita for each DALY averted),
implying that screening would be potentially cost effective, but
nothighlycosteffectiveaccordingtointernationalbenchmarks.
Cervicalcancer—Analysesforcervicalcancer,similarlytothe
breastcanceranalyses,evaluatedstrategiesfortreatmentwithout
screening or treatment combined with routine population
screening according to the Mexican norm. The overall findings
forcervicalcancerinterventionsmirroredthoseforbreastcancer,
withtreatmentatearlierstages(includingtheprecancerousstage
of cervical intraepithelial neoplasia, grade II or III) contributing
greaterbenefitsthantreatmentatlaterstages.Eventherelatively
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were found to be cost effective components of the overall
treatment strategy, based on falling below the threshold of per
capita GDP for each DALY averted. For cervical cancer,
screening was among the most efficient strategies, increasing
overall benefits more than 10-fold. The incremental cost
effectiveness ratio for screening and treatment, compared with
treatment without screening, was around $Int5600 per DALY
averted, which implied that screening would be highly cost
effective.
Chronicobstructivepulmonarydisease—Currentinterventions
for chronic obstructive pulmonary disease (COPD) are aimed
at slowing the progression of the decline in lung function
associated with the disease. We evaluated five main
interventions: intensive smoking cessation programme for
current smokers with a diagnosis of COPD; influenza
vaccinationofCOPDpatientsaged≥65;inhaledbronchodilator
for those with mild COPD; inhaled bronchodilator and
corticosteroid for those with moderate to severe COPD; long
term oxygen treatment (in addition to bronchodilator and
corticosteroid) for those with severe COPD; and treatment of
severeCOPDexacerbations.Wefoundthattreatmentofsevere
exacerbations associated with COPD averted the smallest
number of DALYs, followed by long term oxygen treatment,
inhaled bronchodilator for mild COPD, and then an inhaled
bronchodilatorplusinhaledcorticosteroidformoderatetosevere
COPD. Influenza vaccine for people with COPD and an
intensive smoking cessation programme for those diagnosed
with COPD had the largest benefits in terms of DALYs averted
and were less expensive than interventions directed solely at
patients with later stages of disease. These were also the only
two interventions with average cost effectiveness ratios below
three times GDP per capita in Mexico (both having ratios
between$Int2500and$Int5000).Giventhefocusofthedifferent
interventionsondifferenttargetpopulations,wedidnotconduct
an incremental analysis treating the interventions as competing
choices.
Cardiovascular disease—We evaluated a wide range of
interventions for primary prevention, treatment, and secondary
preventionforcardiovasculardisease.Preventioninterventions
includednon-personalinterventionsinvolvinghealtheducation
through mass media programmes, legislation or voluntary
agreements with the food industry, as well as personal health
service interventions including detection and treatment of high
riskindividualsbasedonbloodpressure,serumcholesterol,and
absolute risk thresholds. The absolute risk approach estimates
thecombinedriskofacardiovasculareventoverthenextdecade
above a given threshold, based on relative risk estimates of
modelled risk factors. We also assessed 30 single interventions
and combinations of interventions for treatment and secondary
prevention relating to acute myocardial infarction, stroke, and
congestive heart failure. All primary prevention interventions
werefoundtobehighlycosteffectiveaccordingtointernational
benchmarks. Among population level (non-personal)
interventions, those aimed at reducing blood pressure and
cholesterol,andsaltreductionthroughlegislation,hadthelowest
costs per DALY. Individual primary prevention interventions
resultedinmuchgreatereffectiveness,althoughtheyweremore
costly per unit of health benefit than the population-wide
strategies. In incremental analyses, population salt reduction, a
comprehensive population combination intervention, and
absolute risk threshold approaches dominated all individual
strategies focusing on either hypertension or cholesterol alone.
Themostaggressivestrategybasedonabsoluteriskthresholds,
focusing on all patients with risks above 5%, was the most
effective but at an incremental cost effectiveness ratio that was
well above the benchmark of three times GDP per capita. All
treatment interventions for myocardial infarction were found
tobehighlycosteffectiveorcosteffectiveincomparingaverage
costeffectivenessratiostoGDPbasedbenchmarks,withcardiac
rehabilitation producing the most attractive cost effectiveness
ratios because of the relatively low cost of this intervention
combined with moderate population level health effects. For
stroke, only post-acute stroke interventions were found to be
highly cost effective, while interventions targeting the acute
period resulted in low health gains at significantly higher costs.
All heart failure interventions were highly cost effective, with
diuretics being the most cost effective in the group. Because
the set of interventions were not mutually exclusive, we have
not reported on a full set of incremental comparisons for the
cluster of interventions relating to cardiovascular disease.
Diabetes—Weevaluatedfourmaininterventionsforsecondary
prevention of type 2 diabetes: blood pressure control, lipid
control, and conventional or intensive glycaemic control. With
a high overall prevalence of diabetes in Mexico, the largest
populationbenefitswouldberealisedthroughglycaemiccontrol.
The average cost effectiveness ratios for conventional and
intensive glycaemic control were about $Int12 500 and $Int13
600 per DALY averted, respectively, implying that glycaemic
control is potentially cost effective at less than two times per
capita GDP. Considering the incremental cost effectiveness of
intensive compared with conventional glycaemic control, the
more intensive strategy had an incremental ratio of around
$Int16 900. Lipid control for patients with diabetes would
produce a much smaller overall population benefit, but at an
average cost effectiveness ratio similar to that for glycaemic
control.Bloodpressurecontrolwouldproduceanoverallbenefit
between that for lipid control and that for glycaemic control.
Thecosteffectivenessratioforbloodpressurecontrol,however,
was considerably lower than those for the other two
interventions. At around $Int8500 per DALY averted, blood
pressure control would be classified as highly cost effective
according to standard international benchmarks.
Sensitivity of results to choice of health
metric
In our base case analysis, we have focused on measuring
population health effects of interventions using DALYs that
reflect differential age weights, such that health outcomes
experiencedduringyoungadulthoodareweightedmoreheavily
than those during childhood or older adult years. We examined
the sensitivity of results to the inclusion of age weights by
recalculatingallhealtheffectsandcosteffectivenessratioswith
equal weights at all ages. The appendix figure on bmj.com
compares the yearly population health effects for all 101
intervention strategies under scenarios with and without age
weights, indicating a high degree of consistency. Examining
theaveragecosteffectivenessratiosinthescenariowithoutage
weighting (shown for all interventions in the appendix table on
bmj.com), we found that only two interventions moved from
one broad category (that is, highly cost effective, potentially
costeffective,notcosteffective)toanother.Thesewerenicotine
replacement therapy, which shifted from not cost effective to
potentially cost effective with the removal of age weights, and
angiotensin converting enzyme (ACE) inhibitors for acute
myocardial infarction, which shifted from potentially cost
effectivetohighlycosteffective;bothoftheseshiftswerebased
on relatively small changes in the ratios. Overall, this analysis
indicated that the results in general were highly robust to the
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of population health benefits.
Discussion
In this study we estimated the population health impacts and
costs for various interventions targeting non-communicable
diseases in Mexico. As in the companion papers in this series
presenting analyses for two world regions,
22-28 we found wide
variation across interventions in both costs and effects; yet we
alsoobservedthat,ineverymajordiseaseclusterweexamined,
at least some of the interventions provided excellent value for
money. At the high value end of the spectrum, several
interventions cost <$Int250 for each year of life they added to
thepopulation—includinginterventionsaimedatheavyalcohol
use, tobacco use, cataracts, and cardiovascular disease risks. At
a small fraction of the per capita income in Mexico, such gains
areconsideredtobeexceptionallygoodvalue,basedonstandard
benchmarks for cost effectiveness analysis.
Economic evaluations in middle income countries like Mexico
often require extrapolation of evidence and assumptions from
othercountriesorfromregionaldatabases.
29Inouranalysis,the
availabilityoflocalepidemiologicalandeconomicinformation,
andexplicitconsiderationoflocalnormsforclinicalandpublic
healthpractice,helpedtoreveallimitationsinthetransferability
of conclusions from one setting to another and to develop
national estimates of cost effectiveness for selected
interventions. For example, distinct features of the screening
norm in force for breast cancer in Mexico have important
implicationsforanalysisoftheeconomicefficiencyofdifferent
intervention strategies. We found that the aggressive screening
policy in place in Mexico for early detection of breast cancer
had an estimated cost effectiveness ratio between one and three
timesGDPpercapita,despiteguidelinesinothercountriessuch
as the US that discourage testing before age 50.
30 As further
liberalisationofMexicannormsforearlybreastcancerscreening
since July 2011 begins to shape practice, information on costs
and expected health effects of wider screening coverage is
essential in preparing for the expected increase in demand for
screening services. Another example of the importance of
incorporating local information in economic evaluation relates
to variation in costs of interventions. For interventions with
intensiveuseofdrugs,differencesacrosssettingsinpurchasing
practices can have an important effect on the costs of these
interventions.
Analyses of the cost effectiveness of an array of interventions
across categories ranging from community services to high
intensity clinical services offers insights that in some cases
contradict the conventional wisdom on value for money within
broad categories of interventions. It is not the case that all
communityandpublichealthinterventionshaveextremelylow
cost effectiveness ratios; neither is it true that high complexity
interventions are universally expensive in relation to the health
gainstheyprovide.Cataractsurgeryseemstobeamongthebest
buys in health interventions in Mexico, less expensive per unit
of health benefit than increasing taxation of tobacco products,
itself a highly cost effective intervention at a little more than
$Int100perhealthyyeargained.Likewise,otherclinicalservices
such as antidepressants and some interventions for secondary
prevention of cardiovascular disease have cost effectiveness
ratios that are well below the threshold of GDP per capita for
eachDALYaverted.Thus,whereconventionalwisdomonvalue
for money in public health and medicine fails to provide an
adequate basis for intervention choice, the development of
rigorous information on costs and health benefits from a wide
range of intervention strategies offers essential information to
planners and policy makers in resource constrained settings.
Information on the cost effectiveness of interventions provides
a formal basis for evaluating efficiency of allocated resources,
to maximise overall population health gains under resource
constraints.Assuch,costeffectivenessisonlyoneconsideration
amongarangeofimportantcriteriainsettingprioritiesforhealth
interventions or designing and evaluating healthcare reform. In
addition to attaining high overall gains in population health,
decision makers in Mexico, as elsewhere, are also concerned
with ensuring that benefits are distributed equitably across the
population. Much has been written about concerns for fairness
with respect to the Mexican reform, and these concerns were
central to the design of the reform and to its subsequent critical
evaluation.
31-33
Another limitation is that the analyses presented here, while
covering a broad scope of different interventions, inevitably
omit some interventions that are relevant to clinical practice
andhealthpolicy.Forexample,althoughwereportonsecondary
prevention for managing risk factors in diabetes, we have not
evaluated the range of available strategies relating to screening
and treatment for microvascular complications of diabetes. On
the other hand, we included in our analyses a strategy of
intensiveglycaemiccontrolfordiabetes,evenasrecentlyrevised
guidelineshaveprompteddebateovertheprosandconsofsuch
a strategy.
34 35 As another example, we report here on two types
of surgery for cataracts used widely in
Mexico—phacoemulsification and conventional extracapsular
cataractextraction—butwehavenotyetevaluatedmanualsmall
incision cataract surgery. As clinical practice guidelines
constitute a moving target, and as new information emerges on
health outcomes and resource requirements associated with
interventions against chronic diseases and other health
challenges,costeffectivenessanalysesrequireperiodicupdating
andrevisiontoincorporatethebestcurrentlyavailableevidence
and to answer the most urgent policy questions.
We also recognise that this study—in presenting an expansive
overview on the range of analyses undertaken across disease
clusters—has summarised results relatively parsimoniously,
without exhaustive details on uncertainty around each point
estimate or sensitivity of each result to particular parameter
values and assumptions. Specific choices with regard to
technology adoption or detailed practice guidelines demand
more precision than what is offered here, along with a more
comprehensivecharacterisationofkeyuncertainties.Theintent
inthisstudy,ontheotherhand,wastoofferabroadperspective
on the comparative costs and health impacts of a wide array of
different interventions and strategies, in view of high level
decision making in the context of health reform. To date, the
results from this study have provided a methodological
foundation for further work on cost effectiveness analysis by
interdisciplinary teams within the Mexican Ministry of Health,
atthesametimethatthefindingshaveinformeddecisionmaking
aroundprovisionandfinancialcoverageforseveralinterventions
and provided an evidence base for other public health policies.
Specific examples include design of national programmes such
as the breast cancer and cervical cancer screening, diagnosis,
and treatment programmes, and national legislation such as the
General Law on Tobacco Control. These results have also been
referenced in discussions around accelerating or delaying
coverage of specific interventions in SSPH.
Overthepast50years,theepidemiologicaltransitioninMexico
has produced a dramatic rise in the importance of
non-communicable diseases. Between 1955 and 2005, the
proportion of all deaths from non-communicable diseases
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5 This rise has presented new
challenges to a health system that traditionally prioritised
programmesforcommunicablediseaseandreproductivehealth.
As major reforms in Mexico have sought to extend healthcare
coverage to the substantial fraction of the population lacking
insurance, and to develop new financial mechanisms to protect
families from catastrophic health spending, evidence on the
costs and health benefits associated with different types of
interventions has been—and will continue to be—an essential
inputtothedevelopmentofeffective,efficient,andfairpolicies.
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RESEARCHWhat is already known on this topic
The advanced epidemiological transition in Mexico has produced a large and growing burden of non-communicable diseases
Health reforms since 2003 in Mexico have dramatically expanded insurance coverage in the population, prompting difficult policy choices
on which services to provide to beneficiaries of the new social insurance programmes
What this study adds
An analysis of the cost effectiveness of 101 interventions targeting nine clusters of non-communicable diseases in Mexico showed that
within each cluster there was at least one intervention that was considered to provide excellent value for money based on conventional
benchmarks
High value can be found even among highly complex clinical services; conversely, public health strategies are not guaranteed to be
highly cost effective
Table
Table 1| Summary of intervention strategies to reduce burden of non-communicable diseases in Mexico, by major disease cluster
Main intervention strategies analysed Disease cluster
Tricyclic antidepressants, selective serotonin reuptake inhibitors, psychotherapy, proactive case management Depression*
Excise taxes, advertising bans, random roadside breath testing, brief primary care advice*, restricted retail access Heavy alcohol use†
Excise taxes, advertising bans, indoor air laws, nicotine replacement therapy* Tobacco use†
Extracapsular cataract extraction, phacoemulsification Cataracts*
Treatment (lumpectomy, radiotherapy, chemotherapy, mastectomy), screening (clinical examination and mammography)† Breast cancer‡
Treatment (lesion removal, radiotherapy, chemotherapy, surgery), screening (cervical smear test, liquid based cytology,
HPV DNA testing)†
Cervical cancer‡
Smoking cessation, influenza vaccination, inhaled bronchodilator, corticosteroid, treatment of severe exacerbations Chronic obstructive pulmonary disease*
Health education through mass media, regulation of dietary salt, blood pressure, and cholesterol lowering drugs*, combined
drug treatment for high risk patients*, single or combined drug regimens for acute and post-acute heart disease and
stroke‡
Cardiovascular disease†
Treatment of hypertension, lipid control, glycaemic control Diabetes*
*Low and medium complexity clinical interventions.
†Community and public health interventions (except where noted otherwise).
‡High complexity clinical interventions (except where noted otherwise).
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RESEARCHFigure
Costs, population health effects, and cost effectiveness of 101 intervention strategies in Mexico, by intervention package
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